Karikari Lab https://validator.w3.org/feed/docs/rss2.html Saliva phosphorylated tau concentration is not associated with Alzheimer’s disease, cerebrospinal fluid or blood biomarkers. Impact of cardiometabolic factors and AD plasma biomarkers on white matter hyperintensities volume in individuals with cognitive complaints from the global south. Plasma biomarkers, brain amyloid-beta pathology, and cortical thickness in a non-Hispanic White and Black/African American middle-aged community cohort: The HCP-CoBRA study Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platform Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials. Plasma soluble TREM2 is associated with plasma pTau-181 and pTau-231 in cognitively normal older adults at risk of Alzheimer’s disease. Clinical Validation of Novel Immunoassays for Plasma Phosphorylated Tau 217, 212, 181, 231, and Brain-Derived Tau Across the Biochemical Spectrum of Alzheimer’s Disease. Head-to-head comparison of plasma p-tau217 immunoassays for incipient Alzheimer’s disease in community cohorts. Treatment-related amyloid clearance (TRAC): a framework to characterize patients in the era of anti-amyloid therapies APOE ε4 potentiates tau related reactive astrogliosis assessed by cerebrospinal fluid YKL40 in Alzheimer’s disease. Association Between the Genetic Risk for Attention-Deficit/Hyperactivity Disorder and Cognitive Function in Older Age: The MYHAT Population-Based Study. The Neighborhoods Study: Examining the social exposome in Alzheimer’s disease and related dementias. Classification accuracies of plasma ptau217 vs. ptau217/Aβ1-42 for brain Aβ pathology in cognitively normal older adults. Understanding Cerebral Blood Flow Dynamics for Alzheimer’s Disease Prevention Through Acute Exercise (flADex): Protocol for a Randomized Crossover Trial. Equivalence of the FCSRT and RAVLT to detect medial Temporal lobe atrophy and tauopathy. CSF total tau as a proxy of synaptic degeneration. The Team Cross-cohort validation and cutpoint estimation of the Janssen plasma p-tau217+ assay in predominantly cognitively normal community studies Publications Principal Investigator Photo Gallery Dr. Thomas K. Karikari and the Biofluid Biomarker Lab Participate in the ARGOnaut Club Voyager Summit 2025 Cohort profile: A community-based prospective cohort study of Alzheimer’s disease and related dementias in the Democratic Republic of Congo Contact Biomarker-based staging of Alzheimer disease: rationale and clinical applications. Exploring New Frontiers in Alzheimer’s Research: Reflections from AAIC Canada Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease. Plasma p-tau212 identifies cognitively unimpaired individuals with emerging amyloid-β pathology From Engineering to Neurodegeneration: A PhD Student’s Path to Clinical Mass Spectrometry Innovation Associations of 18 F-RO-948 Tau PET with Fluid AD Biomarkers, Centiloid, and Cognition in the Early AD Continuum Visit Home Page Vascular risk burden is a key player in the early progression of Alzheimer’s disease. Analytical and clinical validation of Alzheimer’s disease blood biomarkers with a focus on plasma p-tau217. Plasma biomarkers, brain amyloid pathology, and cortical thickness in a diverse middle-aged community cohort: the HCP-CoBRA study Blood phosphorylated tau for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology. Novel ultrasensitive immunoassay for the selective quantification of tau oligomers and related soluble aggregates. Sex differences in Alzheimer’s disease blood biomarkers in a Caribbean population of African ancestry: The Tobago Health Study. Personalized whole-brain neural mass models reveal combined Aβ and tau hyperexcitable influences in Alzheimer’s disease. Thomas Karikari, PhD, and Rebecca Thurston, PhD, Receive University of Pittsburgh Chancellor’s Distinguished Research Awards Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly. Association of plasma biomarkers of Alzheimer’s disease and related disorders with cognition and cognitive decline: The MYHAT population-based study. Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer’s disease. Cerebrospinal fluid p-tau181, 217, and 231 in definite Creutzfeldt-Jakob disease with and without concomitant pathologies. Associations of endogenous estrogens, plasma Alzheimer’s disease biomarkers, and APOE4 carrier status on regional brain volumes in postmenopausal women. Amyloid beta and tau are associated with the dual effect of neuroinflammation on neurodegeneration 18F-Flortaucipir (AV1451) imaging identifies grey matter atrophy in retired athletes. Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression. Karikari Lab